IN2014MN02107A - - Google Patents

Download PDF

Info

Publication number
IN2014MN02107A
IN2014MN02107A IN2107MUN2014A IN2014MN02107A IN 2014MN02107 A IN2014MN02107 A IN 2014MN02107A IN 2107MUN2014 A IN2107MUN2014 A IN 2107MUN2014A IN 2014MN02107 A IN2014MN02107 A IN 2014MN02107A
Authority
IN
India
Prior art keywords
cancer
indoline
derivatives
compounds
useful
Prior art date
Application number
Other languages
English (en)
Inventor
Ji Wang Chern
Ajit Dhananjay Jagtap
Hsiao Chun Wang
Grace Shiahuy Chen
Original Assignee
Annji Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Annji Pharm Co Ltd filed Critical Annji Pharm Co Ltd
Publication of IN2014MN02107A publication Critical patent/IN2014MN02107A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/30Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32Oxygen atoms
    • C07D209/34Oxygen atoms in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45Transferases (2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/26Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32Nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
IN2107MUN2014 2012-04-20 2013-04-03 IN2014MN02107A (en, 2012)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261635931P 2012-04-20 2012-04-20
PCT/US2013/035177 WO2013158373A1 (en) 2012-04-20 2013-04-03 Indolin-2-one derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02107A true IN2014MN02107A (en, 2012) 2015-09-11

Family

ID=49380678

Family Applications (2)

Application Number Title Priority Date Filing Date
IN2105MUN2014 IN2014MN02105A (en, 2012) 2012-04-20 2013-04-02
IN2107MUN2014 IN2014MN02107A (en, 2012) 2012-04-20 2013-04-03

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IN2105MUN2014 IN2014MN02105A (en, 2012) 2012-04-20 2013-04-02

Country Status (13)

Country Link
US (2) US8969361B2 (en, 2012)
EP (2) EP2838538B1 (en, 2012)
JP (2) JP6177879B2 (en, 2012)
KR (2) KR101774861B1 (en, 2012)
CN (2) CN104394868A (en, 2012)
AU (2) AU2013249708B2 (en, 2012)
BR (1) BR112014026182A2 (en, 2012)
ES (2) ES2621257T3 (en, 2012)
IL (2) IL235098A0 (en, 2012)
IN (2) IN2014MN02105A (en, 2012)
RU (2) RU2642463C2 (en, 2012)
TW (2) TWI458709B (en, 2012)
WO (2) WO2013158367A1 (en, 2012)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155301A1 (en) * 2013-03-26 2014-10-02 Piramal Enterprises Limited Substituted bicyclic compounds as inhibitors of ezh2
JP6857662B2 (ja) 2015-11-06 2021-04-14 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft インドリン−2−オン誘導体
CN106831707B (zh) * 2016-12-28 2019-09-20 杭州市西溪医院 作为c-Met激酶抑制剂的苯并杂环类衍生物及其医疗用途
GB201709456D0 (en) * 2017-06-14 2017-07-26 Ucb Biopharma Sprl Therapeutic agents
JP2024504265A (ja) 2020-12-23 2024-01-31 ビーエーエスエフ ソシエタス・ヨーロピア ポリウレタン製造用の新規触媒
CN113307799B (zh) * 2021-05-21 2022-07-19 大连医科大学 一种检测葡萄糖醛酸转移酶1a1荧光探针及其应用
CN113999221B (zh) * 2021-11-04 2024-04-05 南京中医药大学 6-位取代的吲哚酮衍生物及其医药用途
CN114380802B (zh) * 2022-01-07 2023-11-17 贵州大学 一类含咔唑基咪唑盐类化合物及其制备方法和应用
WO2024110395A1 (de) 2022-11-24 2024-05-30 Basf Se Verbesserung der lagerstabilität von hydrofluorolefinen in aminhaltigen polyolkomponenten für die herstellung von polyurethanen

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT351865B (de) 1977-04-01 1979-08-27 Hoffmann La Roche Akarizide mittel
US5543414A (en) * 1994-07-28 1996-08-06 Syntex (Usa) Inc. Achiral amino acid acyl esters of ganciclovir and its derivatives
EA005032B1 (ru) * 1998-05-29 2004-10-28 Сьюджен, Инк. Пирролзамещенные 2-индолиноны (варианты), фармацевтическая композиция (варианты), способ модулирования каталитической активности протеинкиназы, способ лечения или профилактики нарушения в организме, связанного с протеинкиназой
DK1255752T3 (da) 2000-02-15 2007-11-26 Sugen Inc Pyrrolsubstituerede 2-indolinonproteinkinaseinhibitorer
US20090264494A1 (en) * 2002-10-18 2009-10-22 Board Of Regents, The University Of Texas System Use of neuroprotective 3-substituted indolone compositions
MXPA06004438A (es) 2003-10-24 2006-06-20 Schering Ag Derivados de indolinona y su uso en el tratamiento de enfermedades como el cancer.
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
EP1891071B1 (en) * 2005-05-25 2012-02-22 Eli Lilly And Company Cyclopropanecarboxylate esters of acyclovir
US20090305382A1 (en) 2005-09-22 2009-12-10 The Scripps Research Institute Alkoxy indolinone based protein kinase inhibitors
CN1850794A (zh) * 2006-05-30 2006-10-25 中国医学科学院医药生物技术研究所 3-酰胺基取代苯甲酰脲类化合物及其抗肿瘤作用
CN101541788A (zh) 2006-12-11 2009-09-23 Irm责任有限公司 作为激酶抑制剂的化合物和组合物
ES2391912T3 (es) * 2006-12-13 2012-12-03 F. Hoffmann-La Roche Ag Formulación en polvo del valganciclovir
JP2010529161A (ja) 2007-06-12 2010-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インドリノン誘導体及び癌等の症状を治療する際のそれらの使用
US7846793B2 (en) 2007-10-03 2010-12-07 Applied Materials, Inc. Plasma surface treatment for SI and metal nanocrystal nucleation
AU2009221761A1 (en) * 2008-03-07 2009-09-11 Ray W. Exley Treatment of herpes virus related diseases
WO2009142827A2 (en) * 2008-03-28 2009-11-26 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and methods for the treatment of viral infection
PE20100087A1 (es) * 2008-06-25 2010-02-08 Irm Llc Compuestos y composiciones como inhibidores de cinasa
RU2011103189A (ru) * 2008-06-30 2012-08-10 Силин Фармасьютикалз, Инк. (Us) Производные оксиндола
US20100298376A1 (en) * 2009-05-13 2010-11-25 Board Of Regents, The University Of Texas System Use of novel neuroprotective 3-substituted indolone compositions
GB201014374D0 (en) * 2010-08-27 2010-10-13 Univ Greenwich Novel hybrid compounds
JP5909495B2 (ja) * 2010-10-08 2016-04-26 ノバルティス アーゲー スルファミドns3阻害剤のビタミンe製剤

Also Published As

Publication number Publication date
US20130281517A1 (en) 2013-10-24
KR101778095B1 (ko) 2017-09-13
US8969361B2 (en) 2015-03-03
CN104394868A (zh) 2015-03-04
EP2838531A1 (en) 2015-02-25
EP2838531B1 (en) 2016-09-21
TWI496784B (zh) 2015-08-21
WO2013158373A1 (en) 2013-10-24
AU2013249714A1 (en) 2014-11-13
BR112014026182A2 (pt) 2017-06-27
KR20150005630A (ko) 2015-01-14
AU2013249714B2 (en) 2016-12-15
RU2642463C2 (ru) 2018-01-25
RU2014145480A (ru) 2016-06-10
TWI458709B (zh) 2014-11-01
CN104302287B (zh) 2017-12-26
ES2600467T3 (es) 2017-02-09
EP2838538B1 (en) 2017-03-15
IL235097A (en) 2017-07-31
WO2013158373A8 (en) 2014-10-30
JP2015514761A (ja) 2015-05-21
AU2013249708A1 (en) 2014-11-13
TW201350485A (zh) 2013-12-16
IL235098A0 (en) 2014-12-31
US8946282B2 (en) 2015-02-03
EP2838538A4 (en) 2015-09-02
JP6174119B2 (ja) 2017-08-02
JP2015514762A (ja) 2015-05-21
WO2013158367A1 (en) 2013-10-24
EP2838531A4 (en) 2015-12-16
EP2838538A1 (en) 2015-02-25
JP6177879B2 (ja) 2017-08-09
TW201343627A (zh) 2013-11-01
KR101774861B1 (ko) 2017-09-05
IN2014MN02105A (en, 2012) 2015-09-11
RU2014145481A (ru) 2016-06-10
ES2621257T3 (es) 2017-07-03
AU2013249708B2 (en) 2017-03-16
US20130281451A1 (en) 2013-10-24
RU2627706C2 (ru) 2017-08-10
CN104302287A (zh) 2015-01-21
KR20150005600A (ko) 2015-01-14

Similar Documents

Publication Publication Date Title
IN2014MN02107A (en, 2012)
PH12017501888A1 (en) Bromodomain inhibitor
PH12016500722A1 (en) Bromodomain inhibitors
MY194262A (en) Inhibitors of ret
PH12017500276A1 (en) Aminopyrimidinyl compounds as jak inhibitors
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
EP4257591A3 (en) Inhibitors of lysine specific demethylase-1
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
MX2015000129A (es) Derivados de pirimidin pirazolilo.
NZ603478A (en) 2 -aminopyridine derivatives useful as inhibitors of atr kinase
HK1203927A1 (en) Heterocyclic compounds and uses as anticancer agents
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
WO2015144290A8 (en) Pyridyl piperidines
MX377560B (es) Inhibidor de cinasa aurora a.
EA201201676A1 (ru) Гетероарильные соединения и композиции в качестве ингибиторов протеинкиназы
EA201790502A1 (ru) Ингибиторы гистоновых диметилаз
MY174883A (en) Treatment of brain cancer
MX2015013419A (es) Cianoetilpirazolo piridonas aciclicas como inhibidores de janus quinasa.
NZ730585A (en) Indolinone compounds and uses thereof
MX2018008507A (es) Inhibición de proteína relacionada con ataxia telangiectasia y rad3 (atr).
NZ783866A (en) Crystalline forms of c21h22cl2n4o2
MX393992B (es) Compuestos de aminotiazol como inhibidores de la proteina quinasa
CY1125459T1 (el) Συνδυαστικη θεραπεια που συμπεριλαμβανουν αντισωματα εναντια της κλαουδινης 18.2 για την θεραπεια του καρκινου
MX2015010854A (es) Combinaciones de un compuesto inhibidor de mek con un compuesto inhibidor de her3/egfr y metodos de uso.
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease